We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
Effect of intravenous enalaprilat in moderate and severe systemic hypertension.
The antihypertensive effect and tolerability of enalaprilat , an intravenously administered angiotensin converting enzyme inhibitor , was studied in 65 patients with moderate or severe hypertension . In this r and omized , double-blind study , enalaprilat was compared with placebo in 42 ( 22 enalaprilat , 20 placebo )  moderate hypertensive ( diastolic blood pressure [ BP ] 100 to 114 mm Hg ) patients . It was compared with furosemide in 23 ( 12 enalaprilat , 11 furosemide ) severe hypertensive ( diastolic BP 115 to 130 mm Hg ) patients . Enalaprilat ( 1.25 or 5.0 mg ) , placebo ( 5 % dextrose ) or furosemide ( 40 or 80 mg ) was given every 6 hours intravenously up to 48 hours . In the moderate hypertension stratum , the mean supine diastolic BP was significantly ( p less than or equal to 0.01 ) reduced from baseline at all timepoints in the enalaprilat group . These diastolic BP reductions were significantly ( p less than or equal to 0.01 ) greater in the enalaprilat group than the placebo at 1 to 24 hours ( -12 vs -4 mm Hg ) , with 59 % of the patients responding to enalaprilat compared with 30 % of the patients responding to placebo . An even greater reduction ( p less than or equal to 0.01 ) was seen at 25 to 48 hours ( -14 vs -7 mm Hg , with 73 % enalaprilat vs 58 % placebo responders ) . Significant ( p less than or equal to 0.01 ) reductions in mean , supine systolic BP were also seen at 1 to 24 hours ( -22 vs -2 mm Hg ) and 25 to 48 hours ( -24 vs -8 mm Hg ) during the 48 hours of the double-blind treatment phase in the enalaprilat group compared with placebo . ( ABSTRACT TRUNCATED AT 250 WORDS
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .